Akari Therapeutics PLC (NASDAQ:AKTX) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Tuesday.
According to Zacks, “Akari Therapeutics PLC is a biopharmaceutical company. It focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. The Company’s lead drug consist of Coversin is a recombinant small protein, which acts on complement component-C5, preventing release of C5a and formation of C5b-9. Akari Therapeutics PLC, formerly known as Celsus Therapeutics Plc, is based in London, United Kingdom. “
Other equities research analysts have also issued research reports about the stock. Chardan Capital restated a “neutral” rating on shares of Akari Therapeutics PLC in a report on Sunday, September 17th. William Blair restated an “outperform” rating on shares of Akari Therapeutics PLC in a report on Tuesday, July 4th. Canaccord Genuity restated a “buy” rating and issued a $15.00 target price on shares of Akari Therapeutics PLC in a report on Friday, September 22nd. Finally, ValuEngine upgraded shares of Akari Therapeutics PLC from a “strong sell” rating to a “sell” rating in a report on Monday, September 11th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $8.00.
Akari Therapeutics PLC (NASDAQ AKTX) opened at 6.87 on Tuesday. The stock’s market cap is $80.90 million. The firm has a 50 day moving average of $4.17 and a 200-day moving average of $7.23. Akari Therapeutics PLC has a 52-week low of $3.18 and a 52-week high of $22.20.
COPYRIGHT VIOLATION NOTICE: “Akari Therapeutics PLC (AKTX) Rating Lowered to Hold at Zacks Investment Research” was originally posted by Transcript Daily and is the property of of Transcript Daily. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://transcriptdaily.com/2017/09/28/akari-therapeutics-plc-aktx-rating-lowered-to-hold-at-zacks-investment-research-2.html.
An institutional investor recently raised its position in Akari Therapeutics PLC stock. VHCP Management II LLC lifted its position in Akari Therapeutics PLC (NASDAQ:AKTX) by 15.4% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 426,297 shares of the biopharmaceutical company’s stock after acquiring an additional 56,807 shares during the quarter. Akari Therapeutics PLC accounts for 0.8% of VHCP Management II LLC’s portfolio, making the stock its 13th largest position. VHCP Management II LLC owned about 3.62% of Akari Therapeutics PLC worth $1,965,000 at the end of the most recent reporting period. Institutional investors own 26.85% of the company’s stock.
Akari Therapeutics PLC Company Profile
Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.
Receive News & Ratings for Akari Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.